Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, 12 - 65 years, with body weight ≥ 30 kg and ≤ 120 kg~* Documented severe Hemophilia B (FIX activity of ≤ 2%) or tested by the central laboratory at screening~* Subjects who have received FIX products for \> 150 exposure days (EDs) (estimated)~* No confirmed prior history of FIX inhibitor (history of positive FIX inhibitor defined as two consecutive positive tests - a confirmatory test on a second, separately drawn sample shortly after the previous positive test) and confirmed no detectable FIX inhibitors (negative FIX inhibitor defined as \< 0.6 Bethesda Units \[BU\] by the central laboratory at screening~* Subjects can be treated on-demand or under prophylactic therapy~* Signed Informed Consent/Assent~Exclusion Criteria:~* Known hypersensitivity (allergic reaction or anaphylaxis) to any FIX product or hamster protein~* Any known congenital or acquired coagulation disorder other than congenital FIX deficiency~* Platelet count \< 100,000/µL~* Immunocompromised (CD4 count \< 200/mm3), (HIV positive subjects may participate in the study and protease inhibitors and antiviral therapy are permitted, at the discretion of the Investigator)~* Currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment~* Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) concentration \> 5 times (x) the upper limit of normal (ULN)~* Serum creatinine \> 2 x ULN~* Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to enrollment~* Use of an Investigational Medicinal Product (IMP) within 30 days prior to the first rIX-FP administration~* Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to study entry~* Subject currently on a dose and/or regimen of FIX that would preclude participation in the study due to possible increased risk of bleeding because of the requirement to withhold treatment during the PK sampling period~* Suspected inability (e.g., language problem or mental condition) or unwillingness to comply with study procedures or history of noncompliance

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 25 IU/kg dose
- Cohort 2 (Type: EXPERIMENTAL): 50 IU/kg dose
- Cohort 3 (Type: EXPERIMENTAL): 75 IU/kg dose

Based on this trial design, predict the completion outcome and termination type (if applicable).